Media stories about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.5459109210657 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
Get Esperion Therapeutics alerts: Esperion Therapeutics (ESPR) Downgraded by Northland Securities (americanbankingnews.com) Esperion Therapeutics Inc (ESPR) Expected to Announce Earnings of -$1.77 Per Share (americanbankingnews.com) Options Traders Expect Huge Moves in Esperion Therapeutics (ESPR) Stock (zacks.com) CLASS ACTION UPDATE for ESPR, SYMC, and PPG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (finance.yahoo.com) DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (finance.yahoo.com)Shares of Esperion Therapeutics traded up $0.26, reaching $41.49, during trading on Thursday, MarketBeat Ratings reports. The company had a trading volume of 13,680 shares, compared to its average volume of 879,731. Esperion Therapeutics has a one year low of $33.06 and a one year high of $82.68. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.94 and a beta of 2.37.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.56) by ($0.17). During the same quarter last year, the company earned ($1.80) earnings per share. sell-side analysts predict that Esperion Therapeutics will post -6.31 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on ESPR. Northland Securities raised their price target on Esperion Therapeutics from $100.00 to $121.00 and gave the stock a “buy” rating in a research note on Thursday, April 19th. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. Chardan Capital raised their price target on Esperion Therapeutics from $75.00 to $100.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 27th. ValuEngine raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Bank of America reissued an “underperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, May 2nd. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $89.08.
In other Esperion Therapeutics news, major shareholder Target N. V. Biotech bought 50,000 shares of the stock in a transaction on Friday, June 29th. The shares were purchased at an average price of $39.48 per share, with a total value of $1,974,000.00. Following the acquisition, the insider now directly owns 3,182,964 shares of the company’s stock, valued at approximately $125,663,418.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Target N. V. Biotech bought 60,000 shares of the stock in a transaction on Thursday, June 21st. The stock was acquired at an average cost of $38.57 per share, for a total transaction of $2,314,200.00. Following the acquisition, the insider now directly owns 3,132,964 shares in the company, valued at $120,838,421.48. The disclosure for this purchase can be found here. Insiders acquired a total of 410,000 shares of company stock worth $16,190,100 in the last ninety days. Insiders own 32.50% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
No comments:
Post a Comment